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Open access under CC BYThymidine phosphorylase (TP) ﬁrst identiﬁed as platelet derived endothelial cell growth factor (PD-ECGF)
plays a key role in nucleoside metabolism. Human TP (hTP) is implicated in angiogenesis and is overex-
pressed in several solid tumors. Here, we report the crystal structures of recombinant hTP and its com-
plex with a substrate 5-iodouracil (5IUR) at 3.0 and 2.5 Å, respectively. In addition, we provide
information on the role of speciﬁc residues in the enzymatic activity of hTP through mutagenesis and
kinetic studies.
 2009 Elsevier Inc.Open access under CC BY license.Human thymidine phosphorylase (hTP, EC 2.4.2.4), identiﬁed as
the sole endothelial mitogenic and angiogenic factor, belongs to
the pyrimidine nucleoside phosphorylase (PyNP) family. In the
presence of inorganic phosphate, it catalyzes the reversible cleav-
age of the glycosidic bond of pyrimidine 20-deoxynucleotides, most
likely through SN2-like transition state involving nucleobase, 20-
deoxyribose and phosphate. hTP has been found to play a role in
the stimulation of chemotaxis and [3H] thymidine incorporation
into endothelial cells in vitro and angiogenesis in vivo. hTP, func-
tionally active as a homodimer plays a key role in the pyrimidine
nucleoside metabolism, ensuring a sufﬁcient pool of pyrimidine
nucleotides is available for DNA repair and replication (for a de-
tailed review see [1]).
Thymidine homeostasis is of great importance. Imbalances
caused by elevated thymidine concentrations can alter cell growth
and viability. hTP regulates thymidine concentration from reaching
levels that would be inhibitory to endothelial cell proliferation.
Presence of hTP in primary tumors is considered to be a risk factor
leading to aggressive tumor progression, tumor growth and metas-
tasis while its over-expression has been associated with angiopro-y, BioCity, Turku FIN-20521,
thampton General Hospital,
 license.liferative disorders, such as rheumatoid arthritis and psoriasis [2].
The enzymatic activity of hTP has been shown to be indispensable
for its angiogenic activity [3]. Modulating hTP activity could reduce
tumor growth and metastasis as tumors depend on the salvage
pathway for their proliferation. Its role in catalyzing the conversion
of certain prodrugs, such as capecitabine, to anticancer nucleotides
is of great signiﬁcance as it directly interferes with DNA replication
[4,5]. Given these observations, the potential for developing potent
hTP inhibitors as therapeutic agents for cancer treatment and as
anti-angiogenic agents is becoming apparent. A number of inhibi-
tors have been designed to date and tested for their efﬁcacy in
inhibiting hTP, mostly through kinetic studies. Current inhibitors
are mainly substrate analogues, while some purine-based inhibi-
tors and synthetic inhibitors have also been reported [2].
Known PyNP structures to date include enzymes from Esche-
richia coli: uridine phosphorylase (EcUDP) and thymidine phos-
phorylase (EcTP), both in native and bound forms [6–11], the
enzyme from Bacillus stearothermophillus (BsPYNP; [12]), and lastly
the structure of hTP was reported in complex with a small mole-
cule inhibitor [13] and in complex with thymine [14]. Insights
gained from these structures suggest that a conformational change
upon substrate (or inhibitor) binding appears to be essential for the
phosphorolysis reaction to occur. In the two reported structures
hTP both have the active site occupied, suggesting that the enzyme
is in its closed–active conformation. Here, we report the crystal
structures of recombinant native hTP and in complex with 5-iodo-
uracil (5IUR), a substrate with a Ki of 0.48 mM. The structural work
presented here was complemented with mutational and kinetic
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ing the active site of hTP.
Materials and methods
Expression and puriﬁcation of recombinant native hTP and mu-
tants. cDNA clone for hTP was obtained fromMammalian Gene Col-
lection. Stratagene QuikChange site-directed mutagenesis kit was
used to introduce the desired mutations. DNA sequencing con-
ﬁrmed the presence of required mutations. Escherichia coli BL21-
Codon-Plus-(DE3)-RIL cells harboring the recombinant plasmid of
either native hTP or mutants were used to inoculate overnight cul-
tures. Expression of the proteins in TB media was induced by the
addition of 1 mM isopropyl b-D-thiogalactoside. Cells were incu-
bated 3 h post-induction and then harvested by centrifugation.
Cells lysis was carried out in a buffer containing 20 mM Na-citrate
pH 5.7, 100 mMNaCl and EDTA-free protease inhibitor followed by
the addition of lysozyme and mechanical disruption. The lysed
cells were then subjected to centrifugation at 97,000g for 1 h at
4 C. The clariﬁed cell lysate (native or mutant hTP) was loaded
onto a 5-ml Ni2+ His-select column (Sigma) previously equilibrated
with buffer A (20 mM Na-citrate pH 5.7). Sample was loaded and
the column was washed with buffer A before eluting the protein
using an imidazole gradient (0–250 mM). Fractions were analyzed
on a 15% SDS–PAGE and those containing signiﬁcant amounts of
hTP were pooled. Final puriﬁcation was carried out by gel ﬁltration
in buffer C (20 mM Na-citrate pH 5.7, 100 mM NaCl). Eluates were
analyzed on a 15% SDS–PAGE to check purity of the protein before
pooling. Concentration of hTP and mutants was determined using
the BCA assay method (standard BCA Assay, Pierce). Absorbance
was measured at 562 nm. The concentration of hTP was 8.8 mg/
ml and that of the various hTP mutants ranged from 7.5 to
20 mg/ml.
X-ray crystallography. Crystals for hTP and hTP–5IUR complex
were obtained by the hanging drop vapor diffusion method. Crys-
tals of hTP grown in 0.1 M Na-acetate (pH 5.2), 25% PEG 4000 and
0.1 M ammonium acetate belong to P21 space group. Crystals for
the hTP–5IUR complex were obtained after overnight incubation
of hTP with 100 mM 5IUR at 4 C prior to equilibration with reser-
voir solution containing 2.8–3.5 M Na-formate (pH 8.7) at 16 C in
P212121 space group. All datasets were collected at 100 K in the
presence of 25% glycerol as cryoprotectant. Both structures were
solved by molecular replacement method using the program MOL-
REP [15]. PDB code 1UOU [13] was used as search model for hTP–
5IUR complex. The ﬁnal reﬁned structure of the complex has a
crystallographic R-factor (Rcryst) of 22.7% and free R-factor (Rfree)Table 1
Crystallographic data.
hTP–5IUR complex
Space group Orthorhombic P212121
Cell dimensions a = 61.9, b = 67.3, c = 212.3 Å
Resolution range (Å) 50–2.5
Rsymm (%) 5.3 (18.5)
I/rI (outer shell) 22.0 (5.9)
Completeness (outer shell) (%) 94.5 (69.6)
Reﬂections (total/unique) 319,417/33,589
Redundancy 4.4 (2.8)
Number of water molecules 44
Rcryst (%) 22.7
Rfree (%) 28.3
RMSD in bond lengths (Å) 0.007
RMSD in bond angles () 1.3
Ramachandran plot statistics (%) 100
Average B-factor (Å2) A: 38.8; B: 45.2 5IUR(A): 36
PDB codes 2WK6, 2WK6SFof 28.3% (Table 1). hTP from the complex was used to solve the
structure of native hTP. The structure was reﬁned to an Rcryst of
20.7% and an Rfree of 28.4% (Table 1) using CNS [16].
Activity assays and inhibition of hTP by 5IUR. Enzymatic activity
of recombinant and mutant hTP was assayed by the spectrophoto-
metric method [17]. Puriﬁed enzyme (native and mutants) was
prepared to a ﬁnal molarity of 40 nM and was incubated with
0.1 M MES pH 5.5, 0.1 M KH2PO4 pH 5.5 and thymidine (Sigma)
in a total reaction volume of 100 ll. Substrate concentrations
tested ranged from 200 lM to 1.2 mM. Reactions were incubated
at 37 C and stopped by the addition of 900 ll of 0.1 M NaOH. Thy-
mine production was measured by absorbance at 300 nm, where
the difference in the extinction coefﬁcient between thymine and
thymidine is 3400 M1 cm1. Assay results were analyzed with
GraFit (Erithacus Software; [18]) for obtaining the Km, Vmax and
standard error values. Vmax values were then used to calculate kcat.
Enzymatic activity assays for native hTP in the presence of 5IUR
were carried out in order to determine its potency as an inhibitor.
Previous kinetic studies carried out by Razzell and Casshyap [19]
have shown a 61% inhibition of thymidine arsenolysis when
0.64 mM of 5IUR was used. Concentration of native hTP was re-
tained at 40 nM and the substrate concentrations were as previ-
ously described (200 lM to 1.2 mM). Concentrations of 5IUR
were 0.005, 0.01, 0.05, 0.1, 0.15 and 0.2 mM. Assay results were
used to generate Dixon plots for the determination of Ki for 5IUR
[20].
Results and discussion
Details of native and 5IUR complex structures
The crystal structure of native hTP (at 3.0 Å) (Fig. 1A) consists of
two non-crystallographic dimers in the asymmetric unit. All four
copies of hTP contain residues 34–479, residues 32 and 33 can be
observed for chains A and B while only residue 33 can be observed
for molecule C. At the C-terminal end, residue 480 was observed
only in chain B. The crystal structure of hTP–5IUR complex (at
2.5 Å) consists of a dimer per asymmetric unit (Fig. 1B). Both chains
comprise of residues 35–480 with one molecule of 5IUR bound in
the active site of each hTP molecule.
No secondary structure differences were observed between na-
tive hTP, hTP–5IUR complex structure and the previously reported
hTP structures [13,14]. The active site is located at the interface be-
tween the a- and the mixed a/b-domain (Fig. 1A). The N-terminal
helices of the two monomers form the interface and bury a total
surface area of around 1289 Å2 upon dimerization.hTP native
Monoclinic P21
a = 103.5, b = 77.2, c = 100.9 Å, b = 98.0
50–2.97
13.8 (43.7)
6.6 (1.7)
90.5 (39.6)
108,957/33,291
2.3 (1.7)
19
20.7
28.4
0.007
1.4
98.7
.8; 5IUR(B): 38.7 A: 22.7; B: 22.8; C: 34.7; D: 35.5
2WK5, 2WK5SF
Fig. 1. (A) Superposition of hTP molecule in the native (gray) and in complex with 5IUR (light orange). Highlighted in green are the three loops (L1–L3) and in magenta is the
hinge region. (B) Crystal packing of hTP–5IUR complex. The ﬁgures were created using Pymol (www.pymol.org). (C) Stereo view of the active site with bound 5IUR in the hTP–
5IUR complex. Potential hydrogen bonds are illustrated with dotted lines. The electron density map (2Fo  Fc) around 5IUR is contoured at 1.0r level. The ﬁgure was created
using Molscript [24].
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5IUR complex
Of the two substrates that are required for catalysis by hTP,
phosphate is considered to bind ﬁrst, followed by the binding of
thymidine. The phosphate-binding site is proposed to be located
near the active site cleft, between strands b1 and b2 (Fig. 1A;
[12]). Domain movement (once the active site is occupied) is con-
sidered to be essential in bringing the substrates into close proxim-
ity for the reaction to proceed and has been proposed for other
members of the PyNP superfamily as well. Such a movement
depending on the bound and unbound state of the enzyme, has
also been supported based on computational work on EcTP [21].
Structural alignment of bound (1TPT) and unbound (2TPT) EcTP
yielded an rmsd of 0.52 Å for 440 Ca atoms.
Pugmire and Ealick [12] have also suggested that phosphate-
binding leads to the formation of a key hydrogen bond between
the side-chain of His116 and the carbonyl oxygen of Gly205 (corre-
sponding residues His150 and Ala239 in hTP), resulting in the rota-
tion of the a/b-domain with respect to the a-domain by 8.
Subsequent binding of pyrimidine in the active site cleft is thought
to cause a further 20 rotation thereby leading to a fully closed con-
formation [12]. So far the tworeported crystal structures of hTPwere
both in the closed form [13,14], based on which we can argue that
bindingof 5IUR in the active site of hTP leads to closed conformation.
The crystal structure of unbound hTP provided some interesting
ﬁndings. Alignment of the molecule A of the two structures (hTPand hTP–5IUR complex) indicates that they align well (including
the ﬂexible loop regions and the hinge region; Fig. 1A), with an
rmsd of 0.57 Å over 445 Ca atoms. The ‘key hydrogen bond’ be-
tween His150 and Ala239 previously proposed to form the phos-
phate-binding site is present in both bound and unbound hTP
structures. Structural alignment of BsPyNP (1BRW), hTP–5IUR
complex and native hTP revealed no conformational change,
although the ‘key hydrogen bond’ was detected in all cases. Hence,
it is unlikely that only the binding of phosphate would trigger the
formation of this key hydrogen bond as it is also observed in struc-
tures where a water molecule is present instead of a phosphate ion
at the phosphate-binding site.
Previous studies propose that hTP undergoes a nucleophilic
transition state of an SN2-type, the ﬁrst ever to be observed for
the family of N-ribosyl transferases [1]. Since no structure is avail-
able for the transition states of hTP, it is not possible to say conclu-
sively whether any conformational change occurs during catalysis.
It is evident that presence of substrate analogue is not required for
the enzyme to acquire the ‘closed’ conformation. However, it is
possible that the closed conformation observed for both bound
and unbound hTP is favoured by crystal packing, while different
‘conformation/s’ of the enzyme may exist in solution.
Comparison of hTP with other known TP structures
hTP, EcTP and BsPyNP share an overall sequence similarity of
42%. Most of the a-domain and part of the mixed a/b-domain
Table 3
Putative hydrogen bonds between hTP active site residues and 5IUR.
hTP atom IUR atom Distance (Å)
Molecule A Molecule A Molecule B
His116 NE2 N1 2.9 2.7
His116 NE2 O2 3.0 3.1
Arg202 NH1 O4 2.9 3.3
Arg202 NH2 O4 2.7 3.0
Ser217 OG N3 3.1 3.0
Lys221 NZ O2 2.6 2.7
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three PyNPs. The only exception is Val241 in hTP, which corre-
sponds to Phe207 in BsPyNP and Phe210 in EcTP. Overall structural
comparison of hTP (present structures and the two previously re-
ported, i.e., 1UOU, 2J0F), EcTP [1TPT, 2TPT] and BsPyNP (1BRW)]
gave an insight into the topological similarity of the three PyNPs
(Table 2).
The glycine rich loop described in EcTP [22] is also present in
BsPyNP and hTP (residues 144 to 154 in hTP). The loop, preceded
by a b-strand (b2) and followed by a a-helix (a6), was proposed
to have a role in the binding of the catalytic phosphate [22]. In
our structure, however, the phosphate-binding site was occupied
by a water molecule and hence the signiﬁcance of this glycine rich
loop, if any, for the binding of phosphate could not be determined.
Interactions of hTP residues with 5IUR
The active site of hTP consists of residues His116, Ser117,
Leu148, Arg202, Val208, Ile214, Lys221 and Val241. A total of six
potential hydrogen bonds stabilize the binding of 5IUR in the ac-
tive site of hTP (Table 3). His116 directly interacts with 5IUR via
its NE2 group. Almost opposite to His116 is Arg202, bonded via
its amino groups to O4 of 5IUR. The other residues which are also
involved in hydrogen-bonding interactions with 5IUR are Ser217
and Lys221 (Fig. 1C and Table 3).
Eleven hTP residues are involved in potential van der Waals
interactions with 5IUR [13] have suggested that Val208 and
Ile214 of the a-domain and Leu148 and Val241 of the a/b-domain
stabilize the chlorine atom of TPI by forming a hydrophobic pocket.
The iodine atom of 5IUR, appears to be similarly stabilized in the
hydrophobic pocket (Fig. 1C).
Correlation of structural data with results from mutagenesis
experiments
Structural analysis on members of the PYNP superfamily have
revealed several key residues that are conserved among species.
Conserved residues of particular interest are those that are in-
volved in the binding and stabilization of the substrate/inhibitor
in the active site cleft. Using the structural information gained
from the hTP–5IUR complex, a series of mutations were designed
for several amino acids that were seen to line the active site of
the enzyme. Two of the mutants, K115E and R202S, previously re-
ported by Miyadera et al. [23], were repeated to act as controls
(along with native hTP) for the rest of the mutations. Biological
activity of hTP was adjudged by an enzymatic activity assay. The
assay revealed that the native hTP was catalytically active with a
kcat of 8.2 s1. Of the mutations on Lys115, His116, Tyr199,
Arg202, Ile214 and Ser217, only four yielded some degree of enzy-
matic activity (Table 4). As expected the previously characterized
mutants (Lys115Glu and Arg202Ser) were inept at catalyzing the
breakdown of thymidine to thymine.Table 2
Comparison of hTP with other known structures.
PDB codes Root mean square deviation (rmsd) (Å)
hTP–5IUR Native hTP
2J0F (hTP) 0.6 (445) 0.6 (446)
1UOU (hTP) 0.8 (436) 0.9 (437)
1TPT (EcTP; native) 3.3 (435) 3.3 (436)
2TPT (EcTP; complex) 3.2 (435) 3.2 (436)
1BRW (BsPyNP)_ 2.9 (426) 3.0 (426)
The numbers in parentheses are the Ca atoms over which the rmsd values were
calculated.His116 is a residue of key importance in PyNPs. Previous studies
on the equivalent residue of EcTP (His85) by means of targeted
molecular dynamics suggest that this highly conserved residue
might be important for the catalytic mechanism of TP [42]. Nor-
man et al. [13] have also discussed its participation in a proton
shuttling mechanism, where Asp114, Glu225 and Lys222 form a
triad delivering a proton to His116. Mutation of His116 to a phen-
ylalanine or a lysine has a severe effect on hTP as both mutations
completely abolish the enzymatic activity. It is likely that the basic
charge and the ring structure of histidine at this position are an
absolute requirement for the catalytic activity.
hTP amino acid sequence possess only one tyrosine residue
when compared to other members of the PYNP superfamily. It is
quite interesting to note that this sole tyrosine residue is located
at the active site cleft, although it does not form any hydrogen
bond with the inhibitor. Among the different tyrosine mutations
tested, Tyr199Leu and Tyr199Phe reduced the catalytic activity of
hTP, while Tyr199Ala completely abolished it (Table 4). It is possi-
ble that both size as well as polar character of the side chain by vir-
tue of its hydroxyl group is essential for maintaining the structural
integrity of the catalytic site.
Along with the previously characterized Arg202, also involved
in the network of interactions that stabilize 5IUR in the active site
cleft of hTP is Ser217. This residue was observed to be involved in
reinforcing the molecules bound at the active site by means of
hydrogen bonds [13]. In the present study, Ser217 was mutated
to glycine and the mutant assayed for enzymatic activity. No thy-
mine production could be detected, indicating that the mutation
was detrimental to the enzymatic activity. The mutation corre-
sponds to the loss of a potential hydrogen bond involving the hy-
droxyl group of the serine.
Apart from the residues that interact with 5IUR via hydrogen
bonds, a hydrophobic pocket lined by Leu148, Val208, Ile214 and
Val241, contributes to the stabilization of the molecule by holding
the ‘iodine’ atom in place. This is similar to the hTP–TPI complex
[13] where TPI is held in place in the hydrophobic pocket via its
‘chlorine’ atom. Mutational work reported for Leu148 (Lue148Arg)
revealed the loss of enzymatic as well as angiogenic activity. InTable 4
Km, Vmax and kcat values for native hTP and hTP mutants.
Km (mM) (Std. error) Vmax (lM/min) (Std. error) kcat (s1)
Native hTP 0.35 (0.01) 19.7 (2.0) 8.2
K115E – – –
K115A 0.42 (0.04) 16.4 (0.9) 6.8
H116F – – –
H116K – – –
Y199A – – –
Y199L 3.14 (1.0) 10.6 (2.0) 4.4
Y199F 2.1 (0.6) 8.4 (1.0) 3.5
R202E – – –
R202S – – –
I214A 0.74 (0.03) 12.53 (0.3) 5.2
S217G – – –
670 E. Mitsiki et al. / Biochemical and Biophysical Research Communications 386 (2009) 666–670contrast, mutations on Ile214 (another residue contributing to the
hydrophobic pocket) showed reduction in the catalytic efﬁcacy of
the enzyme. The mutations, however, did not abolish the enzy-
matic activity of hTP.
Conclusion
Thymidine phosphorylase, providing pyrimidine nucleotides for
DNA repair and replication, has also been shown to have angio-
genic activity in vivo. Mutational study has established that the
angiogenic activity of hTP is dependent on its enzymatic activity.
As hTP is directly involved in angiogenesis, inhibition of its enzy-
matic activity is thought to be of key importance in the inhibition
of angiogenesis, which in turn will lead to cessation of tumor
growth and metastasis. Inhibitors of hTP can act as anti-angiogenic
agents, signiﬁcantly reducing tumor growth by disrupting the thy-
midine salvage pathway, angiogenesis or metastasis. Several inhib-
itors have been designed for hTP and have mostly been tested in
kinetic studies. Only one crystal structure of hTP in complex with
a small molecule inhibitor has been reported to date (1UOU;
[13]). The present structures of native hTP and hTP–5IUR complex
provide further information about the active site features of hTP.
Site-directed mutagenesis and kinetic analyses on native and se-
lected mutants of hTP have revealed the key role of Lys115,
His116, Tyr199, Arg202, Ile214 and Ser217 in enzyme catalysis.
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